Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01645085 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT01645085 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 88 participants.
The verdict
NCT01645085, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
A study in Healthy Volunteers to Compare the Amount of R406 in Blood When Given Different Formulations of Fostamatinib.
Interventions
- DRUG MCC-based 13% drug loaded tablets
- DRUG Mannitol-based 38% drug-loaded tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01645085
The ClinicalTrials.gov registry entry for NCT01645085 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MCC-based 13% drug loaded tablets is the first listed.
NCT01645085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01645085 about?
NCT01645085 is a clinical study titled "A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib". A study in Healthy Volunteers to Compare the Amount of R406 in Blood When Given Different Formulations of Fostamatinib.
What is the current status of trial NCT01645085?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2012-07. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01645085?
The interventions under investigation include: MCC-based 13% drug loaded tablets (DRUG), Mannitol-based 38% drug-loaded tablet (DRUG).
Who is sponsoring clinical trial NCT01645085?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.